Diplomacy and pharmaceutical policy: A new reality.
When health becomes geopolitical.
What role does the American ambassador have in the meeting that took place at the Ministry of Health with Mr. Adonis Georgiadis in the presence of Kyriakos Pierrakakis?
The meeting discussed the drug, which certainly raises reasonable questions but also intense political interest. What is the role of a diplomatic representative in such a crucial national policy?
Pharmaceutical policy is no longer an exclusively internal matter; international collaborations, investments by multinational companies, and access to innovative treatments are directly linked to geopolitical and economic balances.
Kimberly Guilfoyle’s presence can be interpreted as an indication of intense US interest in the Greek pharmaceutical market, investments by American pharmaceutical companies, which it is no secret seek to strengthen their presence in Europe and especially in countries like Greece that operate as hubs for the wider region. Perhaps it is related to production and research as well as the acceleration of drug approval and distribution processes.
Pierrakakis’ presence is not just a coincidence, the digitalization of the health system is a key axis of reform aimed at the transparency of prescribing, the control of pharmaceutical spending. The questions are, where does cooperation end and where does influence begin.
Is there sufficient safeguarding of national interests? Who ultimately determines drug policy?
The challenge for Greece is clear: to take advantage of international collaborations without giving up its autonomy in policymaking for such a sensitive commodity as medicine.
